- Home
- STTK vs PIM Comparison
STTK vs PIM Comparison
Compare STTK & PIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- PIM
- Stock Information
- Founded
- STTK 2016
- PIM 1988
- Country
- STTK United States
- PIM United States
- Employees
- STTK N/A
- PIM N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- PIM Finance Companies
- Sector
- STTK Health Care
- PIM Finance
- Exchange
- STTK Nasdaq
- PIM Nasdaq
- Market Cap
- STTK 173.6M
- PIM 162.4M
- IPO Year
- STTK 2020
- PIM N/A
- Fundamental
- Price
- STTK $3.84
- PIM $3.37
- Analyst Decision
- STTK Strong Buy
- PIM
- Analyst Count
- STTK 3
- PIM 0
- Target Price
- STTK $10.67
- PIM N/A
- AVG Volume (30 Days)
- STTK 123.8K
- PIM 57.5K
- Earning Date
- STTK 11-07-2024
- PIM 01-01-0001
- Dividend Yield
- STTK N/A
- PIM 8.28%
- EPS Growth
- STTK N/A
- PIM N/A
- EPS
- STTK N/A
- PIM 0.05
- Revenue
- STTK $4,123,999.00
- PIM N/A
- Revenue This Year
- STTK $164.45
- PIM N/A
- Revenue Next Year
- STTK N/A
- PIM N/A
- P/E Ratio
- STTK N/A
- PIM $63.80
- Revenue Growth
- STTK 380.09
- PIM N/A
- 52 Week Low
- STTK $1.33
- PIM $2.90
- 52 Week High
- STTK $11.76
- PIM $3.28
- Technical
- Relative Strength Index (RSI)
- STTK 53.41
- PIM 57.02
- Support Level
- STTK $3.63
- PIM $3.33
- Resistance Level
- STTK $3.94
- PIM $3.42
- Average True Range (ATR)
- STTK 0.22
- PIM 0.04
- MACD
- STTK 0.06
- PIM -0.00
- Stochastic Oscillator
- STTK 64.91
- PIM 56.67
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.
About PIM Putnam Master Intermediate Income Trust
Putnam Master Intermediate Income Trust is a closed-end fund. Its investment objective is to provide high current income and relative stability of net asset value. The fund pursues its goal by investing in U.S. high-grade, high-yield, and international fixed-income securities with limited maturities. The fund's portfolio includes the United States Government and agency mortgage obligations; mortgage-backed securities; corporate bonds and notes, and foreign government and agency bonds and notes.